Shire PLC (SHP) Earns Buy Rating from HSBC
Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by equities researchers at HSBC in a report issued on Tuesday. They presently have a GBX 5,400 ($71.92) target price on the biopharmaceutical company’s stock. HSBC’s target price would suggest a potential upside of 5.99% from the company’s previous close.
A number of other equities research analysts also recently weighed in on the company. Jefferies Group restated a “buy” rating and issued a GBX 6,600 ($87.91) target price on shares of Shire PLC in a research report on Monday, September 12th. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($73.26) target price on shares of Shire PLC in a research report on Monday, September 5th. Shore Capital restated a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 6,300 ($83.91) target price on shares of Shire PLC in a research report on Tuesday, August 23rd. Finally, BNP Paribas restated an “outperform” rating and issued a GBX 5,900 ($78.58) target price on shares of Shire PLC in a research report on Thursday, August 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of GBX 5,841.33 ($77.80).
Shire PLC (LON:SHP) traded up 3.22% during trading on Tuesday, reaching GBX 5095.00. The company’s stock had a trading volume of 4,917,584 shares. The firm’s market capitalization is GBX 34.79 billion. The firm has a 50-day moving average price of GBX 4,943.59 and a 200-day moving average price of GBX 4,416.34. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,562.83.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/shire-plc-shp-earns-buy-rating-from-hsbc-2.html
The firm also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be issued a GBX 3.51 ($0.05) dividend. This represents a yield of 0.07%. The ex-dividend date is Thursday, September 8th.
In other Shire PLC news, insider Bohuon,Olivier acquired 134 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The stock was purchased at an average cost of GBX 4,463 ($59.44) per share, for a total transaction of £5,980.42 ($7,965.40).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Shire PLC and related companies with MarketBeat.com’s FREE daily email newsletter.